Dostarlimab with platinum-based chemotherapy for treating primary advanced or recurrent endometrial cancer with high microsatellite instability or mismatch repair deficiency

Technology appraisal guidance
Reference number: TA1064
Published: 22 May 2025

History

Documents created during the development process.

Final draft guidance

Committee papers (PDF 4.88 MB)

Published:

10 April 2025
Final draft guidance (PDF 229 KB)

Published:

10 April 2025
Equality impact assessment (downloadable version) (PDF 112 KB)

Published:

10 April 2025
Public committee slides (PowerPoint 2.91 MB)

Published:

10 April 2025

Invitation to participate

Final scope (PDF 167 KB)

Published:

31 July 2024
Final stakeholder list (PDF 172 KB)

Published:

31 July 2024
NICE's response to comments on the draft scope and provisional stakeholder list (PDF 220 KB)

Published:

31 July 2024
Equality impact assessment (scoping) (PDF 144 KB)

Published:

31 July 2024

Draft scope documents

Draft scope and provisional stakeholder list comments table (post-referral) (MSWord 44 KB)

Published:

04 June 2025
Provisional stakeholder list (post-referral) (MSWord 35 KB)

Published:

04 June 2025